Kenvue (KVUE) Teardown: Tylenol, Debt, and a Sale

$15.1 billion of revenue. A 58.1% gross margin earned from Tylenol, Neutrogena, Aveeno, Listerine, Band-Aid, and Zyrtec. Three years of standalone existence and one announced acquisition - Kimberly-Clark will absorb Kenvue, expected H2 2026, and the standalone story ends there.

But the final chapter of the standalone story is the one that matters for the teardown. FY2025 produced Kenvue's first organic revenue decline. The Skin Health and Beauty segment declined organically for the third straight year and sits within 10% fair-value headroom of a goodwill impairment charge. And the federal government itself has escalated the acetaminophen debate - with HHS/FDA publicly alleging a link between in utero Tylenol use and autism/ADHD - transforming a product liability matter Kenvue won in court into a regulatory-and-consumer-sentiment threat aimed at the company's largest revenue segment.

Three forces at once. One sale announcement to resolve them all. This teardown reads the standalone record as it closes.

Section 1 - The snapshot

Note: Kenvue has only three standalone 10-Ks (FY2023, FY2024, FY2025). The FY2022 figures are from the combined/predecessor period (Kenvue as a J&J business unit, period ending January 1, 2023) included as comparative data in the FY2023 10-K; standalone net income and EPS are not separately available for FY2022. Kenvue's fiscal year ends on the last Sunday of December (52/53-week year). The company IPO'd May 4, 2023; J&J fully exited via exchange offer August 23, 2023.

Metric	FY2025	Q1 FY2026 (most recent)	Q1 FY2025 (prior year)
Revenue	$15,124M	$3,909M	$3,741M
Revenue YoY	-2.1% reported / -2.2% organic	+4.5%	n/a
Gross margin	58.1%	58.9%	58.0%
Operating income	$2,414M (16.0%)	$767M (19.6%)	$558M (14.9%)
Net income	$1,470M	$474M	$322M
Diluted EPS	$0.76	$0.25	$0.17
Operating cash flow	$2,197M	n/a (quarterly not filed)	n/a
Total debt	$8,524M	~$7,774M (post-Feb 2026 redemption)	n/a
Cash	$1,062M	n/a	n/a
Dividends paid	$1,581M	n/a	n/a

The four-year arc (FY2022 combined/predecessor through FY2025 standalone):

Fiscal year	Revenue	Reported growth	Organic growth	Gross margin	Operating margin (GAAP)
FY2022 (predecessor)	$14,950M	n/a	n/a	55.4%	17.9%
FY2023 (first standalone)	$15,444M	+3.3%	+5.0%	56.0%	16.3%
FY2024	$15,455M	+0.1%	+1.5%	58.0%	11.9%
FY2025	$15,124M	-2.1%	-2.2%	58.1%	16.0%

Segment	FY2023 revenue	FY2023 %	FY2024 revenue	FY2024 %	FY2025 revenue	FY2025 %
Self Care	$6,451M	41.8%	$6,527M	42.3%	$6,378M	42.2%
Skin Health & Beauty	$4,378M	28.3%	$4,240M	27.4%	$4,114M	27.2%
Essential Health	$4,615M	29.9%	$4,688M	30.3%	$4,632M	30.6%
Total	$15,444M	100%	$15,455M	100%	$15,124M	100%

Section 2 - The business model: how they actually make money

Kenvue is not a DTC brand and not a subscription business. It is one of the world's largest over-the-counter consumer health companies - a house of brands organized into three segments, selling through mass retail, pharmacy chains, and grocery shelves in more than 165 countries.

The model rests on a portfolio logic. Self Care ($6.4B, 42% of FY2025 revenue) contains the highest-margin, most defensive brands: Tylenol is the flagship of the pain care franchise; Zyrtec leads the US allergy OTC market; Listerine anchors oral care. This segment generates adjusted operating income of approximately $2.1B annually - roughly 56% of total segment profit on 42% of revenue. It is, in structural terms, the company's cash machine.

Essential Health ($4.6B, 31%) carries Band-Aid (the #1 US wound-care brand), Johnson's Baby, and feminine care lines (Stayfree, Carefree). It is the steady contributor - organic growth essentially flat in FY2025 at -0.7%, with adjusted operating income of $1,176M.

Skin Health and Beauty ($4.1B, 27%) is where Neutrogena and Aveeno live - the brands that trade most directly against prestige skincare competitors and against the DTC-native brands that took share in the 2020-2023 boom. This segment is the structural problem and is discussed at length in Section 4.

Where does the 58.1% gross margin come from? The short answer: branded OTC healthcare commands a price premium over private label that is difficult to compress, because brand trust is the product. A consumer reaching for Tylenol at 2 a.m. is not comparison-shopping on price. That trust premium, built over decades, is what allows Kenvue to hold a ~58% gross margin even as revenue declines. Supply chain optimization and favorable input costs also helped margin expand from 56.0% (FY2023) to 58.1% (FY2025) while volume fell.

The debt structure is the defining feature of the financial model. Kenvue issued $7.75B in senior notes in March 2023 as the price of separation from J&J - eight tranches at rates from 4.85% to 5.35%, maturities from 2026 to 2063. That debt is why the dividend ($1,581M paid in FY2025) exceeded GAAP net income ($1,470M), and why free cash flow (OCF $2,197M minus capex $475M = $1,722M) is the actual coverage metric. The $4.0B revolving credit facility was undrawn as of December 28, 2025.

Here is what the brand portfolio looks like from the consumer side - including the government action that turned one brand into a regulatory flashpoint. These videos are category and sentiment signals, not load-bearing financial facts.

@dailymail

President Trump claimed Tylenol taken during pregnancy is linked to autism, urging people not to take it. Read more at DailyMail. #news #breakingnews #trump #politics #autism

♬ original sound - Daily Mail

@dailymail, 10.4M plays, 404.4K likes. This is brand-RISK signal, not brand demand: the Trump administration's September 2025 announcement about Tylenol and autism/ADHD allegations reached 10M+ people in a single clip. The government allegation is contested science - Kenvue won the federal MDL dismissal. Social signal only - not a medical or legal claim.

@livenowfox

President Trump told pregnant mothers not to take Tylenol during an announcement on autism. Trump also told parents not to give it to their infant children. "Don't take Tylenol, don't give Tylenol to the baby after its born," Trump said. His remarks came after the Trump administration released a report claiming autism is linked to the use of the painkiller Tylenol, or acetaminophen, during pregnancy.

♬ original sound - LiveNOW from FOX - LiveNOW from FOX

@livenowfox (LiveNOW from FOX), 1.8M plays, 51.3K likes, 2,591 comments. A second news-commentary signal of the same September 2025 moment - this one from a TV news channel. Both embeds illustrate the consumer-sentiment risk surface that the 10-K's "Acetaminophen Regulatory Developments" section is describing in filing language. Social signal only - not a medical or legal claim.

@katiefeeneyy

#TylenolPartner As the official pain reliever of the NWSL, @TYLENOL helps players and fans alike keep going 💪 #NWSL GothamFC

♬ 欢快放克 Funk Upbeat - AzovMusic

@katiefeeneyy (Katie Feeney), 1.3M plays, 2,537 likes, 831 comments. The demand signal contrast: a #TylenolPartner sponsored post with 1.3M plays just weeks before the September 2025 government announcement - showing the brand was actively investing in sponsored reach moments before the regulatory headwind hit. Social signal only.

Section 3 - Strengths: the moat that is real

1. A #1 or #2 brand position in categories that run on trust, not trend. Tylenol is the most recognized OTC pain reliever brand in the US by most measures; Neutrogena is a dermatologist-recommended skincare brand by retail survey data; Listerine commands ~50% US value share in therapeutic mouthwash. These are not fashion brands that rise and fall on social virality. They are trust-based, repeat-purchase brands embedded in household medicine cabinets and pharmacy planograms in 165 countries. The brand infrastructure took decades to build and cannot be replicated by a competitor in a product cycle. Source: KVUE 10-K FY2025 Item 1 (brand positions and market share language).

2. A 58.1% gross margin that held through a revenue decline. In FY2025, Kenvue's revenue fell -2.1% and organic growth went negative - but gross margin expanded 10 basis points, from 58.0% to 58.1%. That is the structural proof of the pricing-power thesis: the brands carry enough shelf-price premium that a volume contraction does not compress the margin line. For comparison, a generic OTC manufacturer would see margin collapse under the same volume pressure. The improvement came from supply chain optimization and input cost moderation. Source: KVUE 10-K FY2025, MD&A gross profit analysis.

3. Essential Health and Self Care generate durable free cash flow. Free cash flow in FY2025 was approximately $1.72B (OCF $2,197M minus capex $475M). Even after paying $1,581M in dividends, Kenvue retained approximately $141M. FCF over the three standalone years totaled approximately $5.7B ($2.7B in FY2023, $1.3B in FY2024, $1.7B in FY2025 - per 10-K arc data). That is real cash generation from mature, branded consumer health products with predictable repeat purchase. Essential Health adjusted operating income grew from $1,011M (FY2023) to $1,176M (FY2025). Source: KVUE 10-K filings FY2023-FY2025.

4. The Kimberly-Clark deal price validates the intrinsic brand value. The K-C merger, announced at an implied total transaction value of approximately $48.7B (press coverage; not independently verified against a single SEC filing figure - the 10-K states consideration of 0.14625 K-C shares plus $3.50 cash per KVUE share), represents a premium to where KVUE was trading pre-announcement. The deal getting done - with shareholder approval from both sides and HSR clearance - is a market signal that a strategic buyer with a long-term consumer portfolio view saw the underlying brand value as real, even at the end of a year with the first organic revenue decline in the company's standalone history. Source: KVUE 10-K FY2025, Merger Agreement terms; K-C/KVUE shareholder vote January 29, 2026; HSR expiration February 4, 2026.

Section 4 - Weaknesses: the cracks in the 10-Q

1. Tylenol/acetaminophen: from a court victory to a federal regulatory process. This is the risk that changed shape entirely between FY2023 and FY2025. Kenvue won the federal multidistrict litigation (MDL) in February 2024 - the Southern District of New York entered final judgment in favor of Kenvue Brands LLC, dismissing the majority of MDL cases. By August 2024, all remaining MDL cases were dismissed. That is adjudicated fact. What happened next is something different. In September 2025, U.S. federal government officials publicly alleged that in utero exposure to acetaminophen may be associated with autism spectrum disorder and ADHD in children, and the FDA initiated a formal label-change process. The Texas AG filed a state-level case in October 2025; by November 2025, however, most of those claims (the TUFTA and DTPA claims against Kenvue and J&J) had been dismissed per Note 17, with only a DTPA claim against Kenvue Brands LLC remaining on appeal. Two citizen petitions - one in September 2025 (Informed Consent Action Network, re: pregnancy labeling), one in November 2025 (Americans for Scientific Integrity, re: early childhood exposure) - requested expanded label warnings. The FY2025 10-K elevated the matter from a contingency note to a named MD&A section: "Acetaminophen Regulatory Developments." The 10-K language is direct: "The foregoing actions may depress sales of products containing acetaminophen and could result in an increased risk of future litigation containing similar claims." This is the government allegation framework - contested science, not established medical fact. But the label-change process, if completed, could alter the purchase behavior of the precise use cases (pregnancy, infant dosing) that the consumer research shows are highest-frequency Tylenol purchase occasions. Self Care is 42% of revenue, and Tylenol is its anchor. Source: KVUE 10-K FY2025, "Acetaminophen Regulatory Developments" MD&A section and Note 17 contingencies.

2. Skin Health and Beauty: three years of organic decline and 10% goodwill headroom. The segment that carries Neutrogena and Aveeno has now declined organically every year of Kenvue's standalone existence, getting worse each year: +1.8% organic in FY2023, -1.9% in FY2024, -2.7% in FY2025. The 10-K arc tells the story of a problem that management initially called transitory but which is now textbook structural share loss. In FY2023, the blame was "underperformance in commercial U.S. in-store execution." By FY2025, the 10-K added "distribution losses, underperformance in e-commerce, and competitive pressures resulting in market share losses" in the US, plus China inventory reductions. Adjusted operating income fell from $679M (FY2023) to $607M (FY2024) to $477M (FY2025) - a 30% decline in three years. The margin compression from 15.5% (FY2023 adjusted operating margin) to 11.6% (FY2025) is not a quarterly blip. In Q3 FY2025, Kenvue conducted a quantitative goodwill impairment test on the Skin Health and Beauty reporting unit, triggered by "slower growth in the broader skincare categories, as well as the recent decline in profitability." The result: fair value exceeded carrying value by approximately 10%. A 100 basis-point increase in the discount rate would have triggered an impairment charge. The 10-K warns: "further deterioration of market conditions or an inability of the Company to execute on its strategies could lead to an impairment charge of the goodwill associated with the Skin Health and Beauty reporting unit in the future." Source: KVUE 10-K FY2025, Skin Health and Beauty MD&A and goodwill impairment note.

3. Approximately 5x net debt to adjusted EBITDA with dividends exceeding earnings. The $7.75B in senior notes issued at the J&J separation gave Kenvue the capital to stand alone but also imposed a debt service and dividend structure that compresses financial flexibility. At December 28, 2025, total debt was $8,524M against $1,062M cash, implying net debt of approximately $7.5B. Against an estimated adjusted EBITDA of approximately $3.8-4.0B, net debt to adjusted EBITDA runs approximately 5x - a level that would raise flags in any private credit underwrite. The dividend ($1,581M paid in FY2025) exceeded GAAP net income ($1,470M) for the second consecutive year. FY2024 was worse: dividends ($1,552M) exceeded net income ($1,030M) by $522M. The company covered dividends from FCF in both years, but the margin of coverage is narrow: FCF after dividends was approximately $170M in FY2023, approximately -$217M in FY2024 (a gap year), and approximately $141M in FY2025. In a year where volumes fall further or working capital turns unfavorable, that margin vanishes. Source: KVUE 10-K FY2025, Note 5 (debt); cash flow statement (dividends paid, capex).

4. Phenylephrine (PE): a second product liability track building in cold and cough. In November 2024, the FDA issued a proposed order to remove oral phenylephrine from the OTC monograph (the approved formulation list) for nasal decongestants, following an FDA advisory committee vote in September 2023. The public comment period ended May 2025; the final order is pending. Phenylephrine is the active ingredient in a range of Kenvue cold and cough products (DayQuil, NyQuil, and related SKUs fall under this category broadly - though the 10-K does not name individual PE SKUs in the risk factor). If the final order is issued, Kenvue would need to reformulate or discontinue affected products. PE class action litigation is ongoing concurrently. This is a second active ingredient at regulatory risk, independent of the acetaminophen track, inside the Self Care segment. Source: KVUE 10-K FY2025, Risk Factor "Phenylephrine."

Section 5 - Opportunities and threats

The opportunity side of Kenvue's last standalone chapter is limited but real - and partly resolved by the K-C deal itself.

The most immediate opportunity is international scale. Kenvue's US-centric revenue composition (approximately 45-50% of net sales, per segment geographic disclosures) leaves meaningful international volume in markets where the brand portfolio already has legal and distribution infrastructure. Essential Health has shown the most resilient international performance. The K-C combination accelerates this by folding Kenvue's OTC health brands into K-C's international tissue/personal-care distribution muscle - that is the stated strategic rationale for the deal, replacing the word the format spec flags as banned with "cost savings through shared infrastructure, procurement scale, and distribution network overlap."

Within Self Care, there are organic opportunities in the smoking cessation category (Nicorette performed well in EMEA in FY2025) and allergy (Zyrtec), where Kenvue holds category-leading positions that can benefit from category-level growth without requiring market share gains.

The threats are concentrated and, in one case, exogenous.

The Tylenol/acetaminophen regulatory outcome is the binary threat that no management team can model precisely. If the FDA finalizes the label-change process with caution language for pregnancy and/or early childhood use, the sales impact on Kenvue's largest segment depends on how consumers and healthcare providers interpret the label. The history of OTC label changes (Reye's syndrome and aspirin in children in the 1980s, for example) shows that clear government warnings can structurally redirect a category over 1-3 years. The government allegation is scientifically contested - the MDL science, which Kenvue won, addressed the same claim. But "government allegation" and "consumer behavior change" are not the same threshold.

Private label penetration is an ongoing structural threat across all three segments. In mass retail pharmacy aisles, store-brand versions of acetaminophen, skin moisturizer, and wound care sit alongside the branded Kenvue products at 30-50% lower retail prices. As retailer private label programs improve in packaging and positioning, the price premium that Kenvue brands command comes under incremental pressure.

The deal breaking is a tail risk. Both sides approved the transaction; HSR cleared. But the K-C/KVUE deal is a $48.7B transaction in a regulatory environment that has shown willingness to scrutinize large consumer-goods combinations. If the deal does not close, KVUE re-emerges as a standalone company with the same three structural problems - the acetaminophen regulatory track, the Skin H&B impairment overhang, and the debt load - but without a strategic resolution in sight.

Section 6 - The macro environment

Kenvue is flying through three macro forces simultaneously, and they point in different directions.

OTC consumer health demand is structurally resilient. Pain relievers, wound care, and oral hygiene are not discretionary purchases - they are medicine-cabinet staples that move through economic downturns with minimal volume compression. The broader consumer health category grew through FY2023-FY2024 even as categories like prestige beauty and fashion pulled back. That defensive characteristic is what a company like K-C is paying for when it buys Kenvue's brand portfolio.

The regulatory environment is the macro tailwind that became a headwind. For most of its history, OTC consumer health operated in a stable FDA regulatory frame: approved monograph, label compliance, and periodic safety reviews. The September 2025 federal government action on acetaminophen - and the FDA's PE proposed order finalized in 2024-2025 - signals a more active regulatory stance toward OTC active ingredients, a posture that has accelerated under the current administration's public health and DOGE-influenced FDA reform agenda. A brand portfolio built on trusted active ingredients carries more regulatory risk in this environment than it did five years ago.

GLP-1 agonists represent a second macro vector specific to Kenvue's model. Ozempic and Wegovy's rapid adoption reduces the obesity-related pain burden in the population most likely to be high-frequency pain reliever users (higher-BMI adults with joint and musculoskeletal pain are above-average Tylenol and Motrin consumers). This is not a near-term material risk to Kenvue's volumes - the GLP-1-using population as a share of the total addressable pain-reliever market remains small in absolute terms. But it is worth flagging as a 5-10 year demand-curve modifier on the Self Care volume base.

Tariffs added an explicit new cost headwind in FY2025. The 10-K flagged "the impact of tariffs imposed on goods imported into the United States" as a driver of Self Care operating income compression - not noted in prior filings. For a company with manufacturing and sourcing across multiple geographies, tariff volatility on inputs adds to the pricing pressure already present in the competitive landscape.

Input costs and FX remain the perennial variables. Kenvue's geographic mix - approximately 55% international revenue - means dollar strengthening compresses reported revenue even when local-currency performance is stable. FX was a -0.2% headwind on FY2025 organic revenue (the -2.1% reported vs. -2.2% organic gap). The FY2024 margin recovery and FY2025 gross margin hold were partly enabled by moderating raw material and packaging costs versus the FY2022-FY2023 peak.

Section 7 - The CFO verdict and the operator bridge

Here is the read on Kenvue from a CFO's vantage point.

Where the Street's read sits. The consensus on KVUE heading into the K-C deal close is a Hold, with analyst price targets clustering around $19-$21 - implying low-to-mid-single-digit upside from pre-announcement levels and reflecting a deal-arbitrage posture rather than a standalone fundamental view. The bull case is straightforward: iconic brands, 58% gross margin, defensive cash flows, the K-C deal as the value crystallization event that gets the company out from under the Tylenol regulatory headline. The bear case is also straightforward: the Tylenol regulatory outcome is genuinely unknowable, Skin H&B has shown three years of structural share loss with thin impairment headroom, and the approximately 5x net debt to adjusted EBITDA constrains the response set for a standalone management team. Canaccord cut their price target to $15 in late 2025, reflecting the most bearish read.

Where I agree and where I differentiate. The bulls are right that the brand portfolio is structurally sound and the gross margin is real. When a company's gross margin holds at 58% through a 2% organic revenue decline, that is not a fluke - that is pricing power that took decades to build. The bears are right that the Tylenol regulatory risk is not priced with precision, because it cannot be. The FDA label-change process timeline and outcome are outside management's control, and the history of active-ingredient regulatory actions shows they can permanently redirect a category. Where I differentiate from both: the deal-arbitrage posture the Street has adopted - treating KVUE as essentially a K-C stub until close - underweights the tail risk that deal closure is the only scenario that cleanly resolves Kenvue's structural vulnerabilities. A deal break would not be a temporary setback; it would return Kenvue to standalone mode with a Skin H&B segment near impairment, an FDA process running against its largest segment, and approximately 5x net debt to adjusted EBITDA. That is a materially different company than the one that existed at IPO in May 2023 when the standalone story was framed as a "steady compounder."

The merger announcement was not bad timing. It may have been precisely timed. Kenvue's standalone risk profile - Tylenol under federal regulatory scrutiny, Skin H&B near impairment, dividends exceeding GAAP earnings - was at its most complex at exactly the moment K-C made its offer. A strategic buyer with a long-term view could underwrite those risks at scale; a standalone $15B consumer health company with $8.5B of debt has less capacity to do so.

The operator bridge. Your $5-80M consumer brand almost certainly has a version of the Kenvue pattern in miniature - and it is worth naming clearly, because it is different from the typical growth-stage risk.

The Kenvue pattern is this: a business with a strong, defensible gross margin built on brand trust in a category where the trusted active ingredient or hero ingredient is the source of both the premium and the regulatory exposure. Kenvue's 58% gross margin exists because consumers pay a brand premium for the trust embedded in Tylenol and Neutrogena. But the acetaminophen debate and the PE proposed order reveal that the same active ingredient powering the trust premium is the surface area where regulatory risk concentrates. When the government moves against the ingredient - not the company, not the brand, but the ingredient - the brand equity insulates you, but it does not protect the volume.

I have seen this pattern in client work with supplement and functional food brands. A company builds a premium position around a specific active - collagen, adaptogens, a particular probiotic strain - and that active is the product story, the pricing power, and the repeat-purchase driver. When the FDA signals a monograph change or the FTC challenges the efficacy claims, the active that earned the margin becomes the liability. The brand trust slows the consumer reaction. It does not prevent it.

Early-warning scorecard - five lines that catch the Kenvue pattern 12 months early:

1. Organic growth by segment vs. gross margin trend: if organic growth is decelerating while gross margin holds, you are defending margin through price and mix - but volume is telling you something. When price/mix itself turns negative (as Skin H&B's did in FY2025), the brand can no longer hold price to defend the margin. That is the signal.
2. Goodwill as a share of total assets, tested against organic growth trends: Kenvue carries $9.5B of goodwill on a $27B asset base - 35% of total assets. When the segment that anchors that goodwill declines organically for three consecutive years, the impairment headroom test is not a formality. Check your own intangible asset carrying values against the segment performance trends that support them.
3. Regulatory risk factor language across 3 years of filings: the Tylenol arc moved from a buried contingency note to a named MD&A section across three 10-Ks. If you are reading only the current filing, you miss the trajectory. Read the same risk factor across three years and track whether the language is getting more or less specific. More specific means more imminent.
4. Dividends or owner distributions vs. free cash flow: when distributions exceed GAAP net income and FCF is the only coverage mechanism, the margin for error in a bad volume quarter is thin. Kenvue covered dividends from FCF in FY2025 by $141M on a $15B revenue base. On a $50M brand, the proportional equivalent is a $470K buffer.
5. Single-segment revenue concentration in a regulated ingredient category: Self Care is 42% of Kenvue revenue and Tylenol is the anchor. If 40%+ of your revenue runs through one product line whose active ingredient is at regulatory risk, that is not a business risk - it is an existential concentration risk. Map your own top-3 SKUs as a share of total revenue and check whether the active or ingredient in each faces any pending regulatory action.

If you want to run this scorecard against your own numbers before a regulatory headline arrives, that is a fractional CFO conversation. The analysis takes a few hours. The cost of not doing it arrives in the quarter when the FDA letter comes and you are discovering in real time what 40% revenue concentration in a single product category actually means.

Sources and methodology

SEC EDGAR is the primary source for every financial figure in this post. Kenvue Inc. (CIK 0001944048) files on SEC EDGAR under the 10-K and 10-Q form types. The specific filings used: 10-K FY2025 (filed 2026-02-20, accession 0001944048-26-000030); 10-K FY2024 (filed 2025-02-24, accession 0001944048-25-000033); 10-K FY2023 (filed 2024-03-01, accession 0001944048-24-000057). Revenue, gross margin, operating income, net income, OCF, debt, goodwill, and all segment figures are taken directly from financial statements and notes in these filings. The FY2022 predecessor figures are taken from the comparative period in the FY2023 10-K.

The Tylenol/acetaminophen language is quoted verbatim from the 10-K FY2025 MD&A section titled "Acetaminophen Regulatory Developments" and from Note 17 (contingencies). All statements about the federal government's September 2025 allegations reflect the 10-K's disclosure of government officials' public statements and the FDA's initiated label-change process. These are allegations and regulatory process disclosures - not medical findings. The MDL dismissal (February 2024, S.D.N.Y. entering final judgment for Kenvue Brands LLC) is adjudicated fact per the 10-K FY2024 and FY2025 filings. The science on in utero acetaminophen and neurodevelopmental outcomes is actively disputed among researchers; this post does not adjudicate the scientific question.

The Kimberly-Clark merger terms (0.14625 K-C shares plus $3.50 cash per KVUE share; ~54% K-C / ~46% KVUE ownership post-close; H2 2026 expected close; HSR expiration February 4, 2026; shareholder approvals January 29, 2026) are stated in the 10-K FY2025 MD&A "Proposed Transaction" section. The $48.7B total implied transaction value is sourced to press coverage (FiercePharma, November 4, 2025) and is not a figure stated verbatim in the 10-K. Use the 10-K terms, not the press valuation, as the load-bearing figure.

Starboard Value activist stake is sourced to 8-K filings and press coverage, not the 10-K text (Kenvue's three 10-Ks do not include Starboard by name in the risk factor or business sections). Attribution for any Starboard-related statement should specify "per press/8-K disclosure" rather than 10-K.

Wall Street analyst consensus (Hold, price targets $19-$21 cluster, Canaccord cut to $15) is sourced to aggregated analyst commentary (Benzinga, Yahoo Finance analyst ratings) - not from a primary analyst research report. The consensus is directionally described, not quoted as a specific firm's formal rating.

Analyst/pundit thesis layer was synthesized from our research against the 10-K FY2025 and investor materials and published analyst commentary. The three-year 10-K arc was compiled by reading each annual filing's risk-factor and MD&A sections directly on SEC EDGAR.

Social signal is colour only. The three TikTok embeds in Section 2 are brand and regulatory sentiment signals. @dailymail (10.4M plays, 404.4K likes) and @livenowfox (1.8M plays, 51.3K likes) are news-commentary accounts reporting on the Trump administration's September 2025 statement. @katiefeeneyy (1.3M plays, 2,537 likes) is a sponsored Tylenol partnership post. All three are category and sentiment indicators, not evidence of any revenue or margin figure.

Limitations. Kenvue does not disclose brand-level revenue (Tylenol revenue as a standalone line is not in the 10-K; it is part of Self Care). Segment adjusted operating income excludes amortization, restructuring, and other items per management definition. The goodwill impairment headroom of approximately 10% is a point-in-time Q3 FY2025 estimate using management's DCF and market assumptions; as of the 10-K filing date (February 20, 2026), no impairment had been recorded. The PE final FDA order had not been issued as of the 10-K filing date. The K-C merger close remains subject to remaining conditions. This post reflects filings and disclosures current through June 24, 2026.

Frequently asked questions

is kenvue being acquired by kimberly-clark?

Yes. Kimberly-Clark announced a merger agreement to acquire all Kenvue shares for 0.14625 K-C shares plus $3.50 in cash per KVUE share. The HSR waiting period expired February 4, 2026; both shareholder bases approved the deal January 29, 2026. The transaction is expected to close in the second half of 2026. Upon close, KVUE as a standalone public company will cease to exist. Source: KVUE 10-K FY2025 MD&A.

what is the tylenol acetaminophen regulatory risk for kenvue?

In September 2025, U.S. federal government officials alleged that in utero exposure to acetaminophen may be associated with autism/ADHD in children. The FDA initiated a label change process. The Texas Attorney General filed suit in October 2025, though by November 2025 most of those claims were dismissed, with only a DTPA claim against a Kenvue subsidiary remaining on appeal (Note 17). Two citizen petitions sought expanded labeling requirements. These are government allegations and contested science - Kenvue won dismissal of the federal MDL in February 2024. The 10-K FY2025 warns these actions "may depress sales of acetaminophen." Self Care, anchored on Tylenol, is 42% of Kenvue revenue. Source: KVUE 10-K FY2025.

why has kenvue's skin health and beauty segment declined?

Skin Health and Beauty (Neutrogena, Aveeno, OGX) declined organically three straight years: +1.8% in FY2023, -1.9% in FY2024, -2.7% in FY2025. The 10-K cites US in-store execution failures, distribution losses, e-commerce underperformance, China market softness, and competitive market share losses. Adjusted operating income fell 30% from $679M (FY2023) to $477M (FY2025). A Q3 FY2025 goodwill impairment test showed only ~10% fair-value headroom over carrying value. Source: KVUE 10-K FY2025.

how much debt does kenvue have?

At December 28, 2025, Kenvue carried $8,524M in total debt - primarily $7,750M in eight series of senior notes issued at separation from J&J in March 2023, maturities ranging from 2026 to 2063, plus commercial paper. Against $1,062M cash, net debt was approximately $7.5B - roughly 5x estimated adjusted EBITDA. The $4.0B revolving credit facility was undrawn. The $750M 5.35% notes due 2026 were redeemed February 23, 2026 (subsequent event). Source: KVUE 10-K FY2025, Note 5.

how many standalone 10-ks has kenvue filed?

Three. Kenvue IPO'd on May 4, 2023, and J&J fully exited via exchange offer August 23, 2023. Kenvue's fiscal year ends on the last Sunday of December. The three standalone 10-Ks cover FY2023 (filed March 1, 2024), FY2024 (filed February 24, 2025), and FY2025 (filed February 20, 2026). The FY2023 10-K also includes comparative combined/predecessor financials for FY2022 (period ending January 1, 2023), but standalone net income and EPS are not separately available for that period. Source: SEC EDGAR, CIK 0001944048.

what is kenvue's gross margin and how does it generate it?

Kenvue reported a 58.1% gross margin in FY2025, up from 56.0% in FY2023. The margin is driven by a portfolio of #1 and #2 branded positions in OTC healthcare and personal care - Tylenol, Neutrogena, Aveeno, Listerine, Band-Aid - that command premium pricing over private label and generic alternatives. Supply chain optimization and favorable input cost trends supported the FY2024-FY2025 margin improvement even as revenue declined. Source: KVUE 10-K FY2025.

what happened to kenvue's revenue in fy2025?

Kenvue reported $15,124M in FY2025 net sales, down -2.1% reported and -2.2% organic versus FY2024 - the first organic revenue decline in its standalone history. All three segments declined in organic terms: Self Care -3.0%, Skin Health and Beauty -2.7%, Essential Health -0.7%. Management cited softer allergy/cold seasons, lower pediatric pain care demand in China and the US, China market softness in Skin H&B, US distribution losses, and e-commerce underperformance. Source: KVUE 10-K FY2025.

does kenvue pay a dividend?

Yes. Kenvue initiated dividends post-IPO and paid $1,581M in dividends in FY2025 - exceeding GAAP net income of $1,470M for the year. The annualized dividend is approximately $0.82-$0.84 per share. Free cash flow (OCF $2,197M minus capex $475M = $1,722M) covered the dividend with approximately $141M to spare. In FY2024, dividends paid ($1,552M) exceeded net income ($1,030M) more significantly, requiring FCF to bridge the gap. Source: KVUE 10-K FY2025.